Related Experiment Video
Updated: Jun 19, 2026
08:30
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
Rho Kinase Inhibitors in Glaucoma Management: Current Perspectives and Future Directions.
Eleftherios Chatzimichail1, Eirini Christodoulaki1, Panagiotis A G Konstas2
1Department of Ophthalmology, University Hospital of Basel, Basel, 4031, Switzerland.
Drug Design, Development and Therapy
|April 7, 2025
Summary
Rho kinase (ROCK) inhibitors offer a new approach to treating glaucoma by improving fluid drainage and potentially protecting eye nerves. These novel drugs are as effective as traditional treatments and may enhance surgical outcomes.
Area of Science:
- Ophthalmology
- Pharmacology
- Neuroscience
Background:
- Glaucoma, a leading cause of irreversible blindness, involves optic nerve damage and visual field loss.
- Current glaucoma management primarily uses medications to lower intraocular pressure (IOP).
- Traditional IOP-lowering drugs include prostaglandin analogs, beta-blockers, alpha agonists, and carbonic anhydrase inhibitors.
Purpose of the Study:
- To review Rho kinase (ROCK) inhibitors as a novel class of antiglaucoma medications.
- To discuss their mechanism of action, clinical efficacy, safety, and potential additional benefits.
- To explore future applications of ROCK inhibitors in comprehensive glaucoma management.
Main Methods:
- Review of recent clinical studies on ROCK inhibitors like Ripasudil (K-115) and Netarsudil (AR-13324).
- Comparison of ROCK inhibitors with traditional antiglaucoma medications (beta-blockers, prostaglandins).
- Analysis of emerging evidence on neuroprotective properties and use in conjunction with glaucoma surgery.
Main Results:
- ROCK inhibitors enhance aqueous humor outflow via the conventional pathway.
- Clinical studies show promising efficacy and safety profiles for Ripasudil and Netarsudil.
- ROCK inhibitors are non-inferior to traditional treatments and may offer neuroprotection and improve surgical success.
Conclusions:
- ROCK inhibitors represent a significant advancement in glaucoma pharmacotherapy.
- They offer a dual benefit of IOP reduction and potential neuroprotection.
- Further research into their expanded role in glaucoma management is warranted.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
01:25Glaucoma: Overview
482
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
482
01:27Open Angle Glaucoma: Treatment
368
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
368
01:28Angle Closure Glaucoma: Treatment
403
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
403
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
128
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
128
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
113
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
113